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Targeting the Mitochondria in Heart Failure
A Translational Perspective
Hani N. Sabbah, PHD
VISUAL ABSTRACT
Sabbah, H.N. et al. J Am Coll Cardiol Basic Trans Science. 2020;5(1):88–106.
HIGHLIGHTS
 Cardiac energy deprivation due to mitochondrial dysfunction is characteristic of heart failure.
 Mitochondrial dysfunction contributes to worsening of the heart failure state.
 Pharmacologic targeting of mitochondria in heart failure is an unmet need.
 Mitochondrial dysfunction in heart failure can be reversed with novel experimental drugs.
SUMMARY
The burden of heart failure (HF) in terms of health care expenditures, hospitalizations, and mortality is substantial and
growing. The failing heart has been described as “energy-deprived” and mitochondrial dysfunction is a driving force
associated with this energy supply-demand imbalance. Existing HF therapies provide symptomatic and longevity beneﬁt
by reducing cardiac workload through heart rate reduction and reduction of preload and afterload but do not address the
underlying causes of abnormal myocardial energetic nor directly target mitochondrial abnormalities. Numerous studies in
animal models of HF as well as myocardial tissue from explanted failed human hearts have shown that the failing heart
manifests abnormalities of mitochondrial structure, dynamics, and function that lead to a marked increase in the formation
of damaging reactive oxygen species and a marked reduction in on demand adenosine triphosphate synthesis. Correcting
mitochondrial dysfunction therefore offers considerable potential as a new therapeutic approach to improve overall
cardiac function, quality of life, and survival for patients with HF. (J Am Coll Cardiol Basic Trans Science 2020;5:88–106)
© 2020 The Author. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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M itochondria are intracellulardouble-membraned organellesthat are considered the “power
houses” of eukaryotic cells and, as such, are
most abundant in cardiac muscle cells and
in skeletal muscle type-1 ﬁbers, where high-
energy–requiring processes take place. The
heart, being the most metabolically active or-
gan in the body, possesses the highest con-
tent of mitochondria of any tissue (1),
comprising about 25% of cell volume in hu-
man myocardium (2,3). The primary role of
mitochondria is the generation of adenosine
triphosphate (ATP) from adenosine diphos-
phate (ADP) using macromolecular com-
plexes that form the electron transport
chain (ETC): nicotinamide-adenine dinucu-
leotide dehydrogenase (complex I [CI]), suc-
cinate dehydrogenase (CII), cytochrome bc1
(CIII), and cytochrome c oxidase (CIV) (4).
Protons (Hþ) are pumped from the matrix to
the intercristae space during these reactions,
creating a proton gradient; ATP synthesis
from inorganic phosphate and ADP is driven
by the enzyme ATP synthase (CV) as a result
of protons diffusing back along this gradient
(Figure 1) (5,6). The coupling of substrate
oxidation and ATP formation in the mitochondria
(oxidative phosphorylation) is central to tissue and
organ health (4). Cardiolipin is a key phospholipid
expressed exclusively on the inner mitochondrial
membrane that is required for ETC activity and is
especially important for anchoring soluble cyto-
chrome c to the inner mitochondrial membrane to
facilitate electron transfer from CIII to CIV (7).
Humans produce and consume about 65 kg of ATP
every day, with the heart accounting for about 8% of
ATP consumption daily or about 6 kg (8). About
90% of cellular ATP within the myocardium is used to
meet the enormous energy requirements for
contraction and relaxation (both active processes and
both ATP-dependent) (9). Mitochondrial dysfunction
therefore plays a central role in a wide variety of
metabolic and cardiac disorders, including heart fail-
ure (HF) (10). Dysfunctional mitochondria in skeletal
muscle has been implicated in HF-associated exercise
intolerance (11) and in the pathology of chronic
metabolic disorders such as obesity and type 2
diabetes (12,13).
Because ATP cannot be stored, it is critical that the
rate of ATP synthesis matches the rate of ATP
consumption on a beat-to-beat basis (14). This pro-
cess is accomplished by mitochondrial oxidative
phosphorylation within the ETC using fatty acids as
the primary fuel source (15). Although there are
numerous reasons why a human heart can fail, the
worsening of the HF state can be attributed, in part,
to a mismatch between ATP supply and demand, also
described as an engine “out of fuel” (8). Pathologic
left ventricular (LV) remodeling including chamber
dilation and hypertrophy causes inefﬁciencies that
increase energy demand but concomitantly reduce
the capacity for energy supply (Figure 2) (14). The
subsequent altered bioenergetics attempt to regain
energy homeostasis in the failing heart and are
characterized by changes in substrate utilization,
including an initial up-regulation and subsequent
reduction of glucose utilization and a decrease in
fatty acid utilization (14). Changes in oxidative
phosphorylation are characterized by decreased en-
ergy production, with reductions in oxygen utiliza-
tion, and respiratory-chain and ATP synthase activity.
Changes in high-energy phosphate metabolism asso-
ciated with HF include impaired creatine kinase
energy-transfer mechanism, increased free ADP
levels, and, in advanced HF, reduced ATP content (8).
Mitochondrial dysfunction also contributes to skel-
etal muscle performance limitations by reducing the
ability of the mitochondria to meet the ATP demand
of aerobic, slow-twitch, fatigue-resistant working
muscles (16). Lack of availability of energy at rest and
during activity leads to progressive LV dysfunction
and worsening of the HF state along with abnormal-
ities of skeletal muscle composition that culminates
in exercise intolerance.
Current treatments for chronic HF such as beta-
blockers, angiotensin-converting enzyme inhibitors,
angiotensin-receptor antagonists, and aldosterone
antagonists rely primarily on energy-sparing maneu-
vers such as heart rate reduction and reductions of
preload and afterload that help decrease overall car-
diac workload for their therapeutic effect. Few stra-
tegies that can potentially increase ATP supply have
emerged recently and are likely to undergo clinical
assessment in the short term. The aim of this review
is to describe the role and speciﬁc pathophysiologic
mechanisms of mitochondria dysfunction in HF, as
well as potential agents that target mitochondrial
dysfunction in HF.
ABNORMALITIES OF MITOCHONDRIA IN THE
FAILING HEART
ULTRASTRUCTURAL ABNORMALITIES. It is well
known that structural abnormalities of mitochondria
in HF are present in animal models and in humans.
These abnormalities include hyperplasia, reduced
organelle size or fragmentation, and structural injury
ABBR EV I A T I ON S
AND ACRONYMS
ADP = adenosine diphosphate
ATP = adenosine triphosphate
CI (to V) = complex I (to V)
Drp = dynamin-related protein
ETC = electron transport chain
HF = heart failure
HFpEF = heart failure with
preserved ejection fraction
HFrEF = heart failure with
reduced ejection fraction










PINK = phosphatase and tensin
homolog–inducible kinase
ROS = reactive oxygen species
TAZ = tafazzin
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including loss of electron-dense matrix and disrup-
tion of inner and outer membranes (Figure 3) (17–19).
In dogs with experimentally induced HF, there was a
signiﬁcant increase in the overall number of interﬁ-
brillar mitochondria (hyperplasia) and a signiﬁcant
decrease in the overall average size of mitochondria
relative to normal dogs (17), resulting in impaired
mitochondrial respiratory activity (18). Abnormal
mitochondrial morphology is also observed in car-
diomyocytes of humans with HF (20–22). Human
ischemic and idiopathic dilated cardiomyopathy
are associated with functional mitochondrial abnor-
malities characterized by impaired respiration that
can potentially adversely affect overall energy pro-
duction and contribute to myocardial energy deple-
tion (19).
In dogs with HF, mild to severe mitochondrial
injury, ranging from electron-dense matrix depletion
to myelinization, and mitochondrial membrane
disruption, was observed in 27% of mitochondria
compared with only 3% in normal dogs (p < 0.001)
(17). Electron micrographs showed predominantly
large mitochondria with tightly packed cristae
and electron-dense matrix in cardiac tissue from
normal dogs, whereas tissue from dogs with HF
showed clearance of mitochondrial matrix and
marked disorganization of mitochondrial cristae and
severe mitochondrial injury including inner and outer
membrane disruption and myelinization (17).
Accordingly, the overall mitochondrial injury index
(ratio of the number of injured mitochondria to the
total number of mitochondria multiplied by the
average score of the injury) was signiﬁcantly higher in
dogs with HF versus normal dogs. The extent of
mitochondrial injury and injury index was similar
across all the regions of the heart assessed (LV free
wall, interventricular septum, and right ventricular
free wall), and also correlated with increased plasma
norepinephrine, suggesting a role for sympatho-
adrenergic hyperactivity in mitochondrial dysfunc-
tion in HF (17).
Mitoﬁlin, an inner mitochondrial membrane
structural protein, maintains cristae morphology and
structure. Down-regulation of mitoﬁlin in HeLa cells
using speciﬁc small interfering ribonucleic acid
resulted in mitochondria with abnormal morphology
characterized by disorganized inner membranes,
increased apoptosis, elevated reactive oxygen species
FIGURE 1 Mitochondrial Inner Membrane and Electron Transport Chain
Depiction of mitochondrial inner membrane and electron transport chain consisting of complexes I through V (CI to CV). Reactive oxygen
species (ROS) are generated at CI and CIII. Excessive ROS production can lead to mitochondrial and cardiomyocyte dysfunction by inhibiting
the tricarboxylic acid (TCA) cycle enzymes and adenosine triphosphate (ATP) synthase, and by damaging mitochondrial deoxyribonucleic acid
(mtDNA). CK ¼ creatine kinase; CoQ10 ¼ coenzyme Q10; Cyt C ¼ cytochrome c; e ¼ electrons; Pi ¼ inorganic phosphate. Reprinted with
permission from Sabbah (6) and adapted with permission from Okonko and Shah (5).
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(ROS) production, and overall loss of mitochondrial
function and structure (23). Mitoﬁlin levels were also
reported to be signiﬁcantly reduced in LV tissues
from explanted failed human hearts of both ischemic
and idiopathic dilated cardiomyopathic etiologies
compared with normal donor hearts (24).
Cardiolipin, a key phospholipid located in the
inner mitochondrial membrane, is required to sup-
port energy production. It functions as a cofactor
for mitochondrial transport proteins, including sta-
bilization of supercomplexes (CI, CIII, CIV, and CV)
and mitochondrial cristae and retention of cyto-
chrome c to the inner mitochondrial membrane
(25,26). Cytochrome c is a key electron carrier for
electron transport and also triggers cellular
apoptosis when released from mitochondria into the
cellular cytoplasm. Peroxidation of cardiolipin leads
to the release of cytochrome c into the cytoplasm, a
process that triggers cellular apoptosis by activation
of caspase-3 (27,28). Loss of cardiolipin in HF am-
pliﬁes the production of ROS, which, in turn,
aggravates the peroxidation of cardiolipin. This vi-
cious cycle leads to further mitochondrial dysfunc-
tion and ultimately to cardiomyocyte death (26).
Cardiolipin is also a key regulator of mitochondrial
biogenesis and ﬁssion and fusion dynamics. In dogs
with HF, compared with normal dogs, cardiolipin
synthase-1, a key enzyme in the synthesis of
cardiolipin was signiﬁcantly reduced (29). The same
study in dogs with HF also showed that the
cardiolipin remodeling enzymes tafazzin-1 (TAZ-1)
and acyl-CoA:lysocardiolipin acyltransferase-1 are
dysregulated in HF. Speciﬁcally, TAZ-1 was signiﬁ-
cantly reduced and acyl-CoA:lysocardiolipin acyl-
transferase-1 was signiﬁcantly increased in dogs
with HF compared with normal dogs (29). It is well
known that certain diseases arise from genetic
mutations that adversely impact the ability of car-
diolipin to perform key functional processes. Barth
syndrome, for example, is caused by genetic muta-
tions of TAZ-1 and is clinically manifested as car-
diomyopathy, skeletal myopathy, neutropenia, and
FIGURE 2 Imbalance Between Energy Supply and Demand in the Development of HF
Schematic of the imbalance between energy supply and demand in the development of heart failure (HF). ATP ¼ adenosine triphosphate. Reprinted with permission
from Zhou and Tian (14).
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growth retardation (25). Cardiolipin deﬁciency has
been observed in both animal models of HF and in
explanted failed human hearts (30–32). Gene
expression of TAZ-1 and cytidine diphosphate-
diacylglycerol synthetase-2, a rate-limiting enzyme
in cardiolipin biosynthesis, were shown to be
signiﬁcantly reduced in failing relative to nonfailing
human hearts (30).
ABNORMALITIES OF MITOCHONDRIAL DYNAMICS.
Mitochondr ia l b iogenes i s . Mitochondria have
their own deoxyribonucleic acid (mtDNA) with a ge-
netic code that is distinct from the host-cellular DNA.
Mutations in mtDNA cause a variety of disorders
characterized by altered energy homeostasis (reduced
ATP synthesis) in high-energy tissues such as cardiac
muscle. Mitochondrial turnover or biogenesis and
respiration in both skeletal and cardiac muscle are
regulated by the transcriptional factor peroxisome
proliferator-activated receptor coactivator (PGC)-1a
and PGC-1b (33,34). Expression of these key regula-
tors of energy metabolism is reduced in animal
FIGURE 3 LV Mitochondria in Normal Dogs and Dogs With HF
Transmission electron micrographs of left ventricular (LV) mitochondria in normal dogs and dogs with heart failure (HF). (Top left) Normal dog showing predominantly
normal, large mitochondria with tightly packed cristae and electron-dense matrix, with insert depicting various structural components of mitochondria. (Top right)
Coronary microembolization-induced HF showing mild abnormalities of mitochondria in the form of clearance of electron-dense matrix. (Bottom left) Coronary
microembolization-induced HF showing moderate abnormalities of mitochondria in the form of reduced organelle size and marked disorganization of cristae. (Bottom
right) Coronary microembolization-induced HF showing severe mitochondrial injury with inner and outer membrane disruption and myelinization. ID ¼ intercalated
disk; M ¼ mitochondrion. Reprinted with permission from Sabbah (6) and adapted with permission from Sabbah et al. (17).
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models of HF (35–38). PGC-1a was signiﬁcantly down-
regulated in LV myocardium of dogs with HF, and
phosphorylation was markedly reduced, a dysregu-
lation suggestive of abnormal biogenesis (39). Pa-
tients with HF of diverse etiologies also showed
reductions in mtDNA contents accompanied by re-
ductions in mtDNA-encoded proteins. Impaired
mitochondrial biogenesis was also reported in failing
human hearts, which is possibly the result of defec-
tive mtDNA replication (40). Down-regulation of
estrogen-related receptor a is required for the acti-
vation of mitochondrial genes and increased mito-
chondrial biogenesis was also observed as well as
reduced expression of a number of mitochondrial
genes under transcriptional control of estrogen-
related receptor a. DNA microarray alterations in
PGC-1a and estrogen-related receptor a target gene
sets correlated with LV ejection fraction and
predicted failing versus nonfailing genetic pheno-
types (41). The observations overall suggest that
mitochondrial biogenesis signaling is reduced in HF
and implicate the transcriptional energy metabolic
regulator PGC-1a and its target genes in the patho-
genesis of this maladaptation.
Mitochondr ia l fus ion and ﬁss ion . The dynamic
physiological process of mitochondrial biogenesis is
governed, in part, by fusion and ﬁssion of the or-
ganelles (Figure 4) (24). Mitochondria undergo fusion
to form elongated interconnected mitochondrial
networks and ﬁssion to produce discrete fragmented
mitochondria (42). These processes, both regulated
by speciﬁc mitochondrial ﬁssion and fusion proteins,
ensure maintenance of mtDNA integrity by elimi-
nating mitochondria with damaged DNA and pro-
moting functional mtDNA content (6). Mitochondrial
ﬁssion is facilitated by dynamin-related protein
FIGURE 4 Fusion- and Fission-Mediating Proteins in Normal and HF Dogs
(Left) Fusion-mediating proteins include dominant optic atrophy (OPA)-1 and mitofusin (Mfn)-2 and ﬁssion-mediating proteins include ﬁssion (Fis)-1 and dynamin-
related protein (Drp)-1. (Right) Levels of fusion-mediating proteins and ﬁssion-mediating proteins in left ventricular myocardium of normal dogs (NL) and dogs with
coronary microembolization–induced heart failure (HF). Data are shown as mean  SEM. du ¼ densitometric units. Adapted with permission from Sabbah et al. (24).
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(Drp)-1 and ﬁssion (Fis)-1 and ensures equal division
of mitochondrial numbers during cell division and
mediates removal of damaged mitochondria
(mitophagy) (29,43). Mitochondrial fusion, mediated
primarily by mitofusin (Mfn)-2 in the outer membrane
and by optic atrophy (OPA)-1 in the inner membrane,
allows mixing of intra-mitochondrial proteins and
replacement of damaged mtDNA (29,43). Fusion
maintains the structural integrity of the inner mito-
chondrial membrane and matrix, preserving oxida-
tive phosphorylation and avoiding formation of
cytotoxic oxidizing molecules generated via inter-
ruption of the ETC (43). In animal models of HF, Mfn-
1 and Mfn-2 ablation results in a lethal cardiomyop-
athy (44,45), whereas a reduction of OPA-1 expression
with short hairpin ribonucleic acid results in
increased apoptosis and fragmentation of the mito-
chondria and overexpression of OPA-1 that results in
increased mitochondrial tubularity (46). Mfn-1 or
OPA-1 ablation induces LV hypertrophy (47,48). In LV
myocardium of dogs with chronic HF, Mfn-2 and
OPA-1 were signiﬁcantly down-regulated whereas
FIGURE 5 Mitophagy Signaling in Normal Healthy and Damaged Mitochondria
Schematic diagrams depicting mitophagy signaling in normal healthy mitochondria (top) and in damaged mitochondria (bottom). Activation of phosphatase and tensin
homolog–inducible kinase (PINK)-1 by adenosine monophosphate–activated protein kinase (AMPK) a-2 regulation of PINK-1. (Top) Import of PINK-1 into healthy
mitochondria via translocase of the outer membrane–translocase of the inner membrane (TOM/TIM) import complex. PINK-1 undergoes proteolytic cleavage by
presenilins-associated rhomboid-like (PARL) and cleaved PINK-1 retro-translocates to the cytosol where it is degraded by proteasome. (Bottom) When mitochondria
are damaged, import of PINK-1 is abrogated and it accumulates on the outer membrane, which leads to its phosphorylation by AMPKa2. Phosphorylated PINK-1
recruits the E3 ubiquitin ligase Parkin to the mitochondria from the cytosol. PINK-1 phosphorylates both Parkin and mitofusion (Mfn)-2 promoting ubiquitination (Ub)
of mitochondrial substrates. The valosin-containing protein (VCP) transports ubiquinated mitochondria to the mitophagosome for their degradation. Adapted with
permission from Shires and Gustafsson (49).
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Drp-1 and ﬁssion-1 were signiﬁcantly up-regulated,
indicating a marked dysregulation of ﬁssion and
fusion dynamics (Figure 4) (24). Measures of mito-
chondrial dynamics in humans with HF (LV tissue
from 12 explanted failing human hearts, 6 each failing
due to ischemic and nonischemic etiologies, with
comparisons made with LV tissue from 6 normal
donor hearts) were consistent with those observed in
dogs with experimentally induced HF (24). PGC-1a
protein levels were signiﬁcantly lower in the failing
hearts (both etiologies) relative to the healthy donor
hearts, and a marked dysregulation in the mitochon-
drial ﬁssion and fusion proteins (ﬁssion-1 and Drp-1
were signiﬁcantly increased and Mfn-2 and OPA-1
were signiﬁcantly decreased), and of the mitochon-
drial inner membrane protein mitoﬁlin (which was
signiﬁcantly decreased) (24).
Mitophagy . Mitophagy is a central step in main-
taining the mitochondrial quality control process and
overall health of the cellular mitochondrial pool by
removing mitochondria with damage too severe for
correction through biogenic or fusion-mediated
repair (Figure 5) (49). Mitochondrial ﬁssion suppres-
sion accelerates mitophagy by lowering the threshold
for mitochondrial removal, a maladaptation likely to
promote the elimination of functioning mitochon-
dria, whereas mitochondrial fusion inhibition sup-
presses mitophagy, thus reducing the removal of
toxic, ROS-producing mitochondria. Studies in mito-
chondrial ﬁssion- and fusion-defective murine hearts
and cells showed that Drp-1–mediated mitochondrial
ﬁssion is essential to properly target mitophagy and
restrain mitochondrial permeability transition pore
(MPTP)-mediated cell necrosis (50). Mfn-1 and/or
Mfn-2 deletion caused accumulation of defective
mitochondria without appropriately increasing
mitophagy, whereas Drp-1 ablation interrupted
mitochondrial ﬁssion by increased mitophagy,
causing a generalized loss of mitochondria (50). MPTP
opening in Drp-1–null mitochondria was associated
with mitophagy, cardiomyocyte necrosis, and dilated
cardiomyopathy (50). As eluded to earlier, reduced
FIGURE 6 Down-Regulation of PINK-1, AMPKa2, Parkin, Cytosolic Parkin, pMfn-2, and VCP
α
Bar graphs depicting down-regulation of PINK-1, AMPKa2, Parkin (E3 ubiquitin ligase), cytosolic Parkin, phosphorylated (p) Mfn-2, and
mitochondrial VCP in left ventricular myocardium of NL dogs and HF dogs. All proteins were normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). Data are shown as mean  SEM. Abbreviations as in Figures 3, 4, and 5.
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myocardial levels of fusion-regulating proteins and
increased levels of ﬁssion-regulating proteins are
present in LV myocardium of dogs and humans with
HF (29,51). These observations underscore the
importance of the ability of mitochondria in the
myocardium to serially execute ﬁssion and fusion
followed by mitophagy, which is essential for main-
tenance of mitochondrial health and survival.
Abnormalities of mitochondria occur in car-
diomyocytes of the failing heart and, as mentioned
earlier, include hyperplasia, reduced organelle size,
and disruption of the inner membrane. The underly-
ing causes of these abnormalities are not fully
understood but are believed to result from abnor-
malities associated with mitochondrial ﬁssion,
fusion, and mitophagy. The selective degradation of
mitochondria is an essential process for mitochon-
drial quality control in both health and disease (49).
When mitochondria are normal, phosphatase and
tensin homolog–inducible kinase (PINK)-1 is imported
into the mitochondria via the translocase of the outer
membrane–translocase of the inner membrane import
FIGURE 7 Measures of Mitochondrial Function
(Left) Bar graphs depicting total cardiolipin level (CL) normalized to mitochondrial (MITO) protein (top), total (18:2)4 CL normalized to MITO
protein level (middle), and MITO complex IV activity (bottom) in left ventricular myocardium of NL dogs, untreated HF control dogs (HF-
CON), and dogs with HF treated with elamipretide (HFþELA). (Right) MITO states 3 and 4 respiration (top), MITO membrane potential
(middle), and maximum rate of ATP synthesis (bottom) in left ventricular myocardium of NL dogs, untreated HF-CON dogs, and HFþELA
dogs. All bar graphs are depicted as mean  SEM. Adapted with permission from Sabbah et al. (57). ADP ¼ adenosine diphosphate;
RLU ¼ relative light units.
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complex where it is cleaved by presenilin-associated
rhomboid-like protein (Figure 5). Cleaved PINK-1 is
then retro-translocated to the cytosol and degraded
by proteasome (49). However, when mitochondria are
damaged, import of PINK-1 is terminated and the
protein accumulates on the outer mitochondrial
membrane. PINK-1 is then phosphorylated by aden-
osine monophosphate–activated protein kinase a-2.
Phosphorylated PINK-1 recruits the E3 ubiquitin
ligase Parkin to the mitochondria from the cytosol.
PINK-1 phosphorylates both Parkin- and Mfn-2–pro-
moting ubiquitination of mitochondrial substrates
(49,52). The valosin-containing protein transports
ubiquinated mitochondria to the mitophagosome for
their degradation (Figure 5) (49,53). In HF, this
pathway is dysregulated, resulting in partial deacti-
vation of mitophagy and, hence, the accumulation of
damaged mitochondria. Recent studies in sodium
dodecyl sulfate–extracts of LV tissue, extracts of
mitochondria isolated from LV tissue, as well as
cytosolic fractions of LV tissue of dogs with HF,
showed signiﬁcant down-regulation of PINK-1,
adenosine monophosphate–activated protein kinase
a-2, phosphorylated Mfn-2, Parkin, and valosin-
containing protein in HF dogs compared with in
normal dogs (F. Last, unpublished observations, April
2019) (Figure 6).
MITOCHONDRIAL FUNCTIONAL ABNORMALITIES.
Mitochondria in the failing heart also manifest func-
tional abnormalities highlighted by excessive pro-
duction of ROS with reduced ATP production
(18,19,54). Studies conducted in dogs with chronic
HF showed signiﬁcant reductions in mitochondrial
membrane potential, maximum rate of ATP synthesis,
ATP-ADP ratio, and of 18:2 cardiolipin (a key
FIGURE 8 Changes in LV Myocardium Protein Levels of Various Proteins in NL, HF-CON, and HF-CAP Dogs
Bar graphs depicting changes in LV myocardium protein levels of various metabolic and sarcoplasmic reticulum proteins in NL dogs, untreated
HF-CON dogs CON, and dogs with HF treated with capadenoson (CAP). Data are shown as mean  SEM. *p < 0.05 versus NL; **p < 0.05
versus CON. CS ¼ citrate synthase; SERCA-2a ¼ sarcoplasmic reticulum calcium adenosine triphosphatase; UCP ¼ uncoupling protein; other
abbreviations as in Figures 3, 4, and 7. Adapted with permission from Sabbah et al. (130).
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structural lipid of the inner mitochondrial membrane
on which the mitochondrial ETC resides), and a sig-
niﬁcant increase in cytochrome c in cardiomyocyte
cytosolic fraction (55,56). Measures of key subunits of
mitochondrial complexes showed that CI and CIV
activities were also signiﬁcantly reduced in dogs with
HF relative to normal control animals (57).
Increased opening of the MPTP, decreased mito-
chondrial membrane potential, and decreased mito-
chondrial cytochrome c oxidase and state-3
(ADP-stimulated) respiration have been shown in
cardiomyocytes isolated from dogs with chronic HF
compared with cardiomyocytes isolated from normal
control dogs (55). Treatment of failing car-
diomyocytes with cyclosporine A, a potent inhibitor
of MPTP opening, improving membrane potential,
preserved expression of cytochrome c oxidase,
improved mitochondrial cytochrome c oxidase–
dependent respiration, and tended to enhance the
maximum rate of ATP synthesis (55,56).
Mitochondrial ROS production is dependent on the
mitochondrial membrane potential. The combination
of ROS with elevated calcium concentrations leads to
MPTP opening and subsequently reduced membrane
potential, which decreases the extramitochondrial
phosphorylation potential, adversely impacting cell
function (58,59); a surge in ROS production leads
to cytochrome c release, which initiates cell death
via apoptosis (60,61). Mitochondrial damage to car-
diomyocytes from excess ROS production limits ATP
production to a level insufﬁcient to support the Hþ
pump function during times of high oxidative energy
requirements (62).
Mitochondrial production of ROS occurs at sites
along the inner mitochondrial membrane by ETC
components and in the mitochondrial matrix by
components of the Krebs cycle (63). Under normal
physiological conditions, ROS production is typically
low and is maintained by intracellular and intra-
mitochondrial scavenging systems. Pathological ROS
levels in the heart typically occur with excessive ROS
production and reduced endogenous scavenging ca-
pacity, leading to protein and lipid damage, cell death
cascades, and synchronized breakdowns in the
cellular energy grid (64,65). ROS can damage the
mitochondrial ETC (66), trigger lipid peroxidation
(67), oxidize proteins (68), and cause DNA strand
breaks (69), all of which can lead to mitochondrial
dysfunction (70). Elevated mitochondrial ROS pro-
duction and downstream ROS-mediated damage;
mtDNA damage; decreased enzymatic activity of CI,
CIII, and CIV; and defects in electron transport func-
tion have been reported in animal models of HF
(71–73).
ABNORMALITIES OF SKELETAL MUSCLE IN
HEART FAILURE AND ROLE
OF MITOCHONDRIA
FIBER TYPE COMPOSITION. Exercise intolerance is a
hallmark of chronic HF. Observations of a poor cor-
relation between central hemodynamics and exercise
intolerance in patients with HF shifted interest to
peripheral factors, including skeletal muscle struc-
ture and metabolism (74–79). Exercise intolerance in
HF has been attributed to skeletal muscle atrophy, a
shift from slow-twitch type 1 (oxidative) to fast-
twitch type 2 (glycolytic) muscle ﬁbers, mitochon-
drial abnormalities, and increased inducible nitric
oxide synthase expression with resulting increase of
nitric oxide and causing a decrease in mitochondrial
creatine kinase, a key enzyme necessary for the
transfer of high-energy phosphates from mitochon-
dria to cytosol (80–84). A decrease in the relative
composition of type-1 ﬁbers and an increase in type-2
ﬁbers has been shown in dogs with coronary
microembolization-induced HF (83). This shift from
type-1 to type-2 muscle ﬁbers was associated with
reduced exercise tolerance but not with atrophy of
either ﬁber type (83).
The changes in composition of skeletal muscle
ﬁber type are have also been described in patients
with HF and are also associated with exercise
intolerance (77,81,85). Patients with chronic HF have
a reduced proportion of slow twitch type-1 ﬁbers
and a higher proportion of type-2 fast twitch ﬁbers
in vastus lateralis skeletal muscle biopsies (74,77).
These patients also manifest a reduction in myosin
heavy-chain type I (85), an isoform that is more
abundant in skeletal muscle type-1 aerobic ﬁbers. In
HF, the shift in ﬁber-type composition may be partly
due to skeletal muscle mitochondrial abnormalities
and the associated reduction of ATP synthesis
needed by aerobic type-1 ﬁbers (86); reduction in
ATP production can lead to an adaptation of slow-
twitch type-1 ﬁbers to utilize glycogen as energy
source and thus shifting ﬁber-type composition to-
ward a fast-twitch phenotype.
MITOCHONDRIAL ABNORMALITIES IN SKELETAL
MUSCLE. Under normal physiologic conditions, ATP
production by oxidative phosphorylation in the
mitochondria fulﬁlls most of the ATP demands of
skeletal muscle at rest and during exercise (16).
Mitochondrial dysfunction, therefore, can contribute
to decrements in skeletal muscle performance via loss
of mitochondrial capacity to generate ATP, or reduced
ability to meet ATP demand of working skel-
etal muscle.
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Studies using skeletal muscle biopsies obtained
from the leg vastus lateralis muscle showed marked
functional abnormalities of mitochondria in dogs
with coronary microembolization-induced HF
compared with normal dogs (11). Mitochondria from
skeletal muscle of HF dogs showed signiﬁcant re-
ductions in ADP-stimulated respiration, membrane
potential, and CIV activity compared with skeletal
muscle from normal dogs (11). Levels of inducible
nitric oxide synthase were also signiﬁcantly increased
in HF dogs compared with in normal dogs (11). In this
same study, measurements of cytochrome c and HtrA
serine peptidase-2, a proapoptotic mitochondrial
serine protease involved in caspase-dependent and
caspase-independent cell death, in isolated mito-
chondria showed a decrease of cytochrome c and
HtrA serine peptidase-2 in HF-control dogs compared
with normal dogs, indicating translocation of cyto-
chrome c and HtrA serine peptidase-2 from the
mitochondria to the cytosol, the latter is a known
trigger for activation of caspase-3–dependent and
caspase-3–independent apoptotic pathways (11).
A variety of alterations speciﬁc to skeletal muscle,
including muscle atrophy, myocyte apoptosis, ﬁber-
type changes, defects in oxidative metabolism, and
decreased mitochondrial volume density have been
described in patients with HF (87). Studies using
phosphorus P 31 nuclear magnetic resonance spec-
troscopy clearly demonstrated intrinsic skeletal
muscle metabolic abnormalities in patients with
chronic HF (74). These metabolic abnormalities likely
contribute to skeletal muscle contractile dysfunction
and, consequently, to the reduced exercise capacity
observed in patients with HF.
AGING MITOCHONDRIA AS A MODEL OF
MITOCHONDRIAL ABNORMALITIES
IN HEART FAILURE
The majority of patients with chronic HF are 65 years
of age or older. This is particularly true for patients
with heart failure with preserved ejection fraction
(HFpEF) whose average age is well into the 70s.
Mitochondria are important regulators of the aging
process, and abnormalities in mitochondrial quality
control, including biogenesis and mitophagy, are
considered a major driver of cellular senescence with
aging. Replicative and degradative processes contin-
ually turn over mtDNA within the mitochondrial
matrix. The incidence and frequency of mtDNA mu-
tations increase markedly with age, contributing to
cellular senescence (88,89). In mice expressing error-
prone mtDNA polymerase g defective for proof-
reading activity (which causes increased mutation
frequency), loss of function of DNA proofreading ac-
tivity produced faulty respiratory chain proteins and
premature aging (90–92). In addition, in transgenic
mice, these mitochondrial defects (rapid accumula-
tion of mtDNA mutations) caused premature aging,
dilated cardiac hypertrophy, and death by congestive
HF within 6 months (93). Fusion of healthy mito-
chondria with mitochondria possessing mtDNA mu-
tations during replication can have an impact on the
quality of the mitochondrial pool within the cell
(94–96). As the age-related accumulation of somatic
mtDNA mutations increases, mitochondrial function
is eroded (i.e., mitochondrial energetic output de-
clines, ROS production increases, as does the pro-
pensity for apoptosis), cells are progressively lost
through apoptosis and organ function declines, which
ultimately leads to symptoms when the number of
cells in a given organ declines below the minimum
necessary to maintain normal function (97).
Mitochondrial efﬁciency and capacity to generate
ATP in skeletal muscle is particularly susceptible to
advancing age. The theoretical maximum capacity for
mitochondrial ATP production and mitochondrial
volume density in the human quadriceps are reduced
in sedentary versus active subjects, as is the ﬂux per
mitochondrial volume, indicating that the observed
capacity loss is due to both reduced mitochondrial
content and quality (98). Mitochondrial respiratory
capacity and coupling control of skeletal muscle
mitochondria also decline with advancing age; spe-
ciﬁcally, respiratory capacity and the proportion of
respiration coupled to phosphorylation are lower in
older adults (99). These ﬁndings suggest that the ca-
pacity of skeletal muscle mitochondria to produce
electrochemical potential and to couple this to ADP
phosphorylation is diminished with advancing age
(99).
In addition to loss of mitochondrial capacity,
mitochondrial quality is reduced in aged skeletal
muscle. Coupling of oxidative phosphorylation de-
clines with age in human (100) and mouse
(86,101,102) skeletal muscles. Reduced coupling of
oxidative phosphorylation was also observed in
young sedentary adults compared with age-matched
control subjects, supporting a vital role for physical
activity in the maintenance of mitochondrial quality
(103). In aging skeletal muscle, controllers of skeletal
muscle biogenesis and quality are disrupted, espe-
cially PGC-1a, a key regulator of mitochondrial
biogenesis (104–106). Age-related declines in PGC-1a
expression in skeletal muscle have been demon-
strated in human and rodent models (107–110). Dete-
rioration in mitochondrial quality control is another
important aspect of aging and HF on mitochondrial
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dysfunction in skeletal muscle. The efﬁciency of
mitophagy in skeletal muscle is impaired with age
(111–113).
POTENTIAL THERAPEUTIC INTERVENTIONS
A number of therapeutic breakthroughs in the treat-
ment of HF have substantially improved patient
outcomes; however, there have been few break-
throughs in HF treatment over the past decade. The
current treatment paradigm for patients with heart
failure with reduced ejection fraction (HFrEF) in-
volves systemic blockade of maladaptive neurohor-
monal systems to attenuate progressive cardiac
remodeling and improve clinical outcomes. Nearly all
of these treatments have relied on reducing cardiac
workload through a decrease in heart rate, preload,
and afterload. The concurrent hemodynamic effects
of these therapies such as bradycardia and decreased
preload and/or afterload limit the achievement of
optimal therapy intensity in some patients and rarely
achieve improvements in quality-of-life indicators
such as an improvement in exercise tolerance.
Furthermore, existing therapies provide symptom
relief and clinical beneﬁt but do not adequately
address the molecular abnormalities of HF, under-
scoring the unmet need to develop more effective and
complimentary therapy for these patients, including
treatments that target myocardial and skeletal muscle
energetics through modulation of mitochondrial
function in the failing heart. What follows is a brief
description of some novel therapies that seek to
derive beneﬁts in the treatment of HF by targeting or
partially targeting the mitochondria.
ELAMIPRETIDE. Elamipretide (SS-31, MTP-131,
Bendavia, Stealth BioTherapeutics, Newton, Massa-
chusetts) is a water-soluble, aromatic-cationic
mitochondria-targeting tetrapeptide that readily
penetrates and transiently localizes to the inner
mitochondrial membrane and associates with car-
diolipin to restore mitochondrial bioenergetics (7,114).
As discussed, mitochondrial cardiolipin is essential for
the proper assembly and stability of the ETC to ensure
optimal mitochondrial function, including biogenesis,
fusion and ﬁssion, respiration, regulation of cristae
formation, mtDNA stability and segregation, protein
import, as well as the function and organization of the
respiratory complexes into supercomplexes for
oxidative phosphorylation (25,115,116).
Studies in dogs with coronary microembolization-
induced chronic HF showed that 3 months’
treatment with daily subcutaneous injections of
elamipretide improved LV systolic function and pre-
vented progressive LV dilation without affecting
heart rate, blood pressure, or systemic vascular
resistance (57). Elamipretide also elicited a normali-
zation of mitochondrial function evidenced by
improved respiration, normalization of membrane
potential, reduced ROS formation, and improved
maximum rate of ATP synthesis (Figure 7) (57). These
improvements were accompanied by reduction of
plasma biomarkers of N-terminal pro–B-type natri-
uretic peptide and proinﬂammatory cytokines
including tumor necrosis factor-a, interleukin-6, and
C-reactive protein. In LV tissue obtained from these
dogs, chronic therapy with elamipretide reversed the
dysregulation of mitochondrial ﬁssion (ﬁssion-1 and
Drp-1) and fusion (Mfn-2 and OPA-1) proteins and
PGC-1a protein levels, supporting observations of
improved mitochondrial respiration, maximum rate
of ATP synthesis, and LV function (51). The dysregu-
lation in cardiolipin and determinants of cardiolipin
synthesis and remodeling, including cardiolipin
synthase-1, TAZ-1, and acyl-CoA:lysocardiolipin
acyltransferase-1 were also normalized after 3 months’
therapy with elamipretide (24).
Long-term treatment with elamipretide also
restored skeletal muscle ﬁber-type composition to a
more normal distribution (increased proportion of
skeletal muscle type-1 ﬁbers relative to skeletal
muscle type-2 ﬁbers) in dogs with HF. Elamipretide
also improved mitochondrial function in skeletal
muscle myoﬁbers isolated from dogs with chronic HF
and reduced levels of inducible nitric oxide synthase
(11), changes that would be expected to lead to
improved exercise tolerance (81). In a recent study,
elamipretide treatment rapidly improved mitochon-
drial oxygen ﬂux, CI and CIV activities, and
supercomplex-associated CIV activity in freshly
explanted failing ventricular tissue from children and
adults (117). These effects were independent of car-
diolipin remodeling and suggest that the improve-
ment in mitochondrial function was likely mediated
through improved coupling of the mitochondrial
supercomplex.
A phase 1/2 ascending single-dose study of elami-
pretide (4-h infusions of 0.005, 0.05, and0.25mg/kg/h)
in 36 patients with HFrEF showed that elamipretide
was well tolerated and signiﬁcantly reduced LV end-
diastolic (–18 ml; p ¼ 0.009) and end-systolic
(–14 ml; p ¼ 0.005) volumes in the highest dose
cohort (118). No serious adverse events were reported
in any of the cohorts and blood pressure and heart
rate remained stable. Two phase 2 clinical trials
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examining the effects of elamipretide in patients with
HFrEF (The Effect of Multiple Injections of Elami-
pretide on Various Measures of Heart Function in
Patients With Chronic Heart Failure With a Reduced
Ejection Fraction; NCT02788747) and in patients with
HFpEF (A Study to Evaluate the Effects of 4 Weeks’
Treatment With Subcutaneous Elamipretide on Left
Ventricular Function in Subjects With Stable
Heart Failure With Preserved Ejection Fraction;
NCT02814097) are underway.
PARTIAL ADENOSINE A1 RECEPTOR AGONISTS.
Adenosine is a purine nucleoside that exerts a variety
of physiological actions by binding to adenosine cell
surface receptor subtypes A1, A2a, A2b, and A3, acting
as a cytoprotective modulator that links cardiac
function to metabolic demand (119). The car-
dioprotective effects of adenosine are primarily
mediated by activation of the A1 receptor subtype
(120,121). Potential ways that adenosine A1 receptor
activation might improve HF include enhancement of
cardiomyocyte energetics, calcium homeostasis, and
cardiac structure and function (119). Adenosine A1
receptor activation results in downstream inhibition
of adenyl cyclase and reduction in intracellular levels
of cyclic adenosine monophosphate (122), promoting
a cardioprotective state by reducing sympathetic
overactivation and enhancing atrial natriuretic pep-
tide release (123,124). Adenosine A1 receptors
also modulate mitochondrial KATP channels via acti-
vation of protein kinase C, which reduces mitochon-
drial protein transition pore opening, improving
mitochondrial function under hypoxic conditions
(125). Activation of the adenosine A1 receptor using
the selective agonist N6-cyclopentyladenosine simi-
larly prevented phenylephrine-mediated car-
diomyocyte hypertrophy and cardiac ﬁbrosis, and up-
regulated adenosine A1 receptor expression in a rat
model of compensated hypertrophy (126). The results
suggest that adenosine A1 receptor agonism might
mitigate a1-adrenoceptor–stimulated cardiac remod-
eling and subsequent cardiac dysfunction (126).
Activation of adenosine A1 receptors using full
agonists is limited by adverse effects, including
bradycardia, atrioventricular block, vasoconstriction,
negative inotropy and dromotropy, sedation, and
antidiuretic effects (127,128). These undesirable ef-
fects can be overcome by the use of partial A1 receptor
agonists (129). The beneﬁts of partial adenosine A1
receptor agonists for the treatment of HF, therefore,
lie in their ability to protect the failing myocardium
by limiting triggers of cell injury and death and
potentially by providing the necessary energy to the
working myocardium (130).
In dogs with microembolization-induced chronic
systolic HF, 12 weeks of therapy with oral capa-
denoson, a partial adenosine A1 receptor agonist,
improved LV systolic function and prevented pro-
gressive LV enlargement, as evidenced by an
improvement in LV ejection fraction and a reduction
of LV end-systolic volume (130). Treatment with
capadenoson also signiﬁcantly decreased plasma
norepinephrine and plasma N-terminal pro–B-type
natriuretic peptide. Histomorphometric ﬁndings
showed that capadenoson signiﬁcantly decreased
volume fraction of interstitial ﬁbrosis, oxygen diffu-
sion distance, and myocyte cross-sectional area and
increased capillary density (124). Capadenoson also
normalized expression of mitochondrial uncoupling
proteins-2 and -3, mitochondrial citrate synthase, and
sarcoplasmic reticulum calcium ATPase-2a activity
(Figure 8) (130). Capadenoson treatment did not
induce bradycardia or lower systemic blood pressure.
Issues with central adverse effects of vertigo and
dizziness observed with capadenoson in a clinical
trial in patients with stable angina pectoris (suggest-
ing that the degree of adenosine A1 receptor agonism
was too high) (131), as well as low solubility, which
hampered tablet development (132), led to the iden-
tiﬁcation and development of neladenoson bialanate
(Bay1067197, Bayer HealthCare Pharmaceuticals,
Montville, New Jersey), a prodrug currently being
evaluated in clinical trials for the treatment of HF
(132). In 2 small pilot trials in patients with HFrEF,
oral neladenoson bialanate treatment was well toler-
ated and no atrioventricular conduction disorders or
neurological adverse effects were observed (133). In
the ﬁrst study that assessed single-dose neladenoson
bialanate 30 mg in 11 patients receiving background
beta-blocker therapy, the drug was well tolerated and
no second- or third-degree atrioventricular block was
detected on 48-h ambulatory electrocardiographic
monitoring (133). In the second study, the double-
blind, placebo-controlled PARSiFAL (Partial Adeno-
sine Receptor Agonist in Heart Failure) study, 7 days’
treatment with either 10 mg or 20 mg daily in 31 pa-
tients receiving optimal HF therapy (all patients were
receiving beta-blockers) was also well tolerated and
no episodes of second- or third-degree atrioventric-
ular block, detrimental effects on heart rate or blood
pressure, or clinically relevant neurological adverse
effects were observed (133). There was no signiﬁcant
difference, however, in ejection fraction among study
groups. Two phase 2 dose-ﬁnding trials, PANTHEON
(A Trial to Study Nelandenoson Bialanate Over
20 Weeks in Patients With Chronic Heart Failure
With Reduced Ejection Fraction; NCT02992288) and
PANACHE (A Trial to Study Nelandenoson Bialanate
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Over 20 Weeks in Patients With Chronic Heart Failure
With Preserved Ejection Fraction; NCT03098979), are
underway to assess the efﬁcacy and safety of nela-
denoson bialanate (dose range 5 to 40 mg/day) in
patients with HFrEF and HFpEF, respectively (134).
CONCLUSIONS
The burden of HF in terms of health care expendi-
tures, hospitalizations, and mortality is growing in
the United States and worldwide and will likely
continue to increase with the aging of the population
(1,6). Current therapies for HF produce beneﬁt by
reducing cardiac workload by lowering heart rate and
loading conditions, which reduces myocardial energy
demands. The recent recognition that the failing
heart is “energy deprived” and that mitochondrial
dysfunction is a driving force associated with this
energy imbalance in the heart has led to the evalua-
tion of mitochondria as therapeutic target in HF.
Mitochondrial dysfunction in the heart leads to
reduced ATP synthesis and excessive formation of
damaging ROS. In this review, we have described
abnormalities of mitochondrial structure, function,
and dynamics in the failing heart and brieﬂy dis-
cussed studies of novel agents that target or partially
target mitochondrial dysfunction in HF. The struc-
tural, dynamic, and functional abnormalities
described herein, coupled with excessive ROS pro-
duction, are undoubtedly instrumental in mediating
progressive mitochondrial cellular injury and
dysfunction that culminate in progressive worsening
of HF. Correcting mitochondrial dysfunction to
enhance the energy supply of the failing heart to meet
the desired energy needs offers considerable
potential to improve cardiac function, reduce symp-
toms, and improve exercise tolerance in HF, and ul-
timately offer improved quality of life and survival
for patients, and reduce the overall economic burden
of this condition.
TRANSLATIONAL OUTLOOK. Although our under-
standing of mitochondrial dysfunction in HF has
markedly improved over the past several years,
application of this newly gained knowledge toward
the development of drugs that target mitochondrial
dysfunction in HF remains in its early stages. Ques-
tions remain as to what particular aspects of mito-
chondrial dysfunction should be targeted, such as
biogenesis, mitophagy, ﬁssion, and fusion, or the ETC
complexes that are likely to yield the best outcomes.
Another issue is the conditions under which the
therapy is applied and likely to lead to a positive
outcome in a given HF patient population. Should
one expect improvements under resting conditions
or, more likely, during exercise when energy de-
mands on mitochondria are highest? Outcomes may
vary depending on the stage of the disease and its
form (HFrEF or HFpEF). Answers to these and many
other questions will be helpful in developing target-
speciﬁc drugs and in designing appropriate clin-
ical trials.
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